Objective To evaluate the clinical effectiveness of Periocline (2% minocycline hydrochloride ointment) versus Yakang (metronidazole stilus) for treating chronic periodontitis in adults by means of meta-analysis. Methods The following electronic databases as PubMed, The Cochrane Library, EMbase, CNKI, CBM and WanFang Data were searched on computer from inception to July, 2012, and the references of all selected studies were also retrieved to collect the relevant randomized controlled trials (RCTs) on periocline vs. Yakang for chronic periodontitis. According to the inclusion and exclusion criteria, two reviewers independently screened studies, extracted data, and evaluated the methodological quality of the included RCTs. Then meta-analysis was performed using RevMan 5.0 software. Results A total of 7 RCTs involving 737 patients were included. The results of meta-analysis showed that there were no significant differences in probing depth (MD=0.26, 95%CI −0.35 to 0.87, P=0.40), clinical attachment level (MD=−0.10, 95%CI −0.75 to 0.54, P=0.75), sulcus bleeding index (MD=0.12, 95%CI −0.30 to 0.53, P=0.59), and plaque index (MD=0.07, 95%CI −0.09 to 0.22, P=0.41) between the Periocline group and the Yakang group. Conclusion The current evidence shows that based on periodental non-surgical treatment, Periocline is similar to Yakang in improving the symptoms of chronic periodontitis in adults. However, given the low methodological quality and the limited sample size of most included studies, this conclusion still needs to be further proved by conducting more strictly-designed, high-quality and large-scale RCTs. The long-term effectiveness of those 2 treatment modalities also needs to be observed in a longer follow-up duration.
OBJECTIVE To investigate the effect of the endoexpander pressure of continuous and constant pressure expansion on the drug permeability. METHODS The expanders were divided into two groups, the normal expansion and the continuous and constant pressure expansion (4.6 kPa). Each expander was filled with 0.2% Metronidazole, then the expanders were immersed wholly in normal saline and sealed totally. At several intervals over 72 hours, the surrounding saline was sampled and the drug concentration of the sample was measured respectively. RESULTS Both groups were permeable to the Metronidazole and the concentration outside the expander would reach the effective concentration in 48 hours. The drug concentration of the continuous and constant pressure expansion was higher than that of the normal one and there was significant difference between the two groups (P lt; 0.01). CONCLUSIO The endoexpander pressure in continuous and constant pressure expansion can enhance the drug permeability. In view of this, in the course of continuous and constant pressure expansion, 0.2% Metronidazole can be used to prevent and control the infection.
Objective To evaluate the effectiveness and safety of radiosensitizer metronidazole amino acidum natrium (CMNa) for esophagus carcinoma. Methods Databases including The Cochrane library, PubMed, EMbase, CBM, CNKI, VIP and WanFang Data were searched from their establishment dates to Feb. 1st 2012 for randomized controlled trials (RCTs) of CMMa for esophagus carcinoma. Two reviewers independently screened literature and assessed the quality of the included studies and extracted data. Meta-analysis waw conducted using RevMan 5.1 software. Results A total of 17 RCTs involving 1 475 patients met the inclusion criteria. Results of meta-analyses showed that: a) As for short-term response, the total effectiveness of the experimental group given CMNa plus radiotherapy was higher than the control group given radiotherapy alone (OR=3.51, 95%CI 2.44 to 5.07, Plt;0.000 01). b) Significant differences were found in the quality of life, and one and two year survival rates (OR=2.90, 95%CI 1.91 to 4.39, Plt;0.000 01; OR=1.95, 95%CI 1.21 to 3.15, P=0.006). In accordance with the P-value of 0.05, there was a significant difference in three-year survival rate (OR=2.28, 95%CI 1.16 to 4.49, P=0.02). c) As for safety, no significant differences were found in radiation pneumonitis, radiation esophagitis, myelosuppression and mucous membrane reactions. Conclusion CMNa plus radiotherapy has beneficial effects in the treatment of esophagus carcinoma and improves 1, 2 and 3-year survival rates, but more RCTs on the quality of life and safety evaluation are needed.
Objective To analyze the effectiveness and effect on pregnant outcome about living preparation of lactobacillus versus metronidazole in the treatment of bacterial vaginosis in pregnancy. Methods We searched PubMed, The Cochrane Library, VIP, CNKI, Wangfang, CBM, FMJS, and FEBMT to identify randomized controlled trials (RCT) of living preparation of lactobacillus versus metronidazole for bacterial vaginosis in pregnancy. The quality of the included trials was assessed. RevMan 5.0.24 software was used for meta-analysis. Results Eight trials involving 1 687 patients were included. The results of meta-analysis showed: no significant difference was found in the effectiveness between the two groups (RR=1.04, 95%CI 1.00 to 1.08, P=0.08); living preparation of lactobacillus had lower recurrence rate and lower premature delivery rate compared with metronidazole (RR=0.16, 95%CI 0.06 to 0.43, P=0.0004; RR=0.56, 95%CI 0.33 to 0.94, P=0.03); no significant differences were found in premature rupture of membrane, puerperal infection, infant of low-birth weight, infant infection, and infant jaundice between the two groups. Conclusion The effectiveness about living preparation of lactobacillus versus metronidazole for bacterial vaginosis in pregnancy is similar, but living preparation of lactobacillus has lower recurrence rate and lower premature delivery rate, the others of effect on pregnant outcome are similar.
Objective To assess the effectiveness of local delivery of metronidazole as an adjunct to scaling and root planing (SRP) versus SRP alone in patients with chronic periodontitis. Methods We searched six major electronic databases including CNKI, PubMed, EBSCO, OVID, ScienceDirect, and Springrlink from establishment to May 2009. Randomized controlled trials (RCTs) comparing metronidazole plus SRP with SRP alone for at least 1 month of follow-up were included. The methodological quality of included trials was assessed by the method recommended by the Cochrane Collaboration and pooled analysis was conducted using Stata 10.0 software. Results Seven RCTs met the inclusion and exclusion criteria. A significant mean reduction in probing depth with WMD –0.43 and 95%CI –0.72 to –0.13 for the combined metronidazole and SRP was observed, but there were no statistical significant differences at the clinical attachment level between the two treatments with WMD –0.23 and 95%CI –0.53 to 0.06. Conclusion Metronidazole as an adjunct to SRP could reduce probing depth in the treatment of chronic adult periodontitis.
Objectives To evaluate the effect of metrinidazole treatment after conventional hemorrhoidectomy pain in patients with third and fourth degree hemorrhoids. Methods We searched the Cochrane Library (Issue 1 2009), PubMed (1966 to March 2009), EMbase (1974 to March 2009), SCI (1974 to March 2009), CBM (1978 to March 2009), CNKI (1994 to March 2009), and VIP (1989 to March 2009) to identify randomized controlled trials or quasi- randomize controlled trials of metronidazole versus placebo for treating post hemorrhoidectomy pain. We evaluated the quality of the included studies by using the Handbook 4.2.6 recommend standards and analyzed data using the Cochrane Collaboration’s RevMan 4.2.10. Results We included seven randomized controlled trials or quais-randomized controlled trials (n=553). Meta-analyses showed that there were statistical differences between metronidazole and placebo in pain after hemorrhoidectomy and the use of an additional dose of analgesia. Conclusions The current evidence shows that metronidazole relieves the pain after conventional hemorrhoidectomy and reduces the additional used of analgesics. Further high quality, large sample randomized controlled trials should be carried out.
ObjectivesTo systematically review the efficacy of living preparation of lactobacillus for bacterial vaginosis (BV) during pregnancy.MethodsPubMed, Web of Science, Medline (OVID), CNKI, WanFang Data, VIP and CBM databases were electronically searched to collect randomized controlled trials (RCTs) of living preparation of lactobacillus for BV during pregnancy from inception to September 30th, 2019. Two reviewers independently screened literature, extracted data and assessed risk of bias of included studies, then, meta-analysis was performed by RevMan 5.3 software.ResultsA total of 21 RCTs involving 2 930 patients were included. The results of meta-analysis indicated that: living preparation of lactobacillus was superior to metronidazole in effective rate (RR=1.05, 95%CI 1.02 to 1.07, P=0.000 4), premature delivery rate (RR=0.49, 95%CI 0.32 to 0.73, P=0.000 4), premature rupture of membrane rate (RR=0.54, 95%CI 0.38 to 0.77, P=0.000 7), infant of low-birth weight rate (RR=0.45, 95%CI 0.22 to 0.94, P=0.03) and puerperal infection rate (RR=0.60, 95%CI 0.39 to 0.94, P=0.03).ConclusionsThe current evidence shows that, living preparation of lactobacillus is superior to metronidazole for BV during pregnancy, and the incidence of adverse pregnancy outcomes (preterm delivery, premature rupture of membranes, low birth weight, puerperal infection) after treatment is lower. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify above conclusions.